Serious fungal infections in Portugal

Acknowledgments

The authors thank Rita Roquette for her assistance in consulting the Diagnostic Homogeneous Groups database, made ​​available of the Central Administration Health System.

References

[1] http://censos.ine.pt Accessed 20 May 2016

[2]http://ecdc.europa.eu/en/publications/Publications/tuberculosis-surveillance-monitoring-Europe-2015.pdf Accessed 25 May 2016

[3]https://www.dgs.pt/estatisticas-de-saude/estatisticas-de-saude/publicacoes/portugal-doencas-oncologicas-em-numeros-2014.aspx Accessed 3 June August 2016

[4] http://www.life-worldwide.org/ Accessed 11 August 2016

[5] Rodriguez-Tudela JL, Alastruey-Izquierdo A, Gago S, Cuenca-Estrella M, León C, Miro JM, Nuñez Boluda A, Ruiz Camps I, Sole A, Denning DW (2015) Burden of serious fungal infections in Spain. Clin Microbiol Infect 21:183-189. doi: 10.1016/j.cmi.2014.07.013. Epub 2014 Oct 29.

[6] https://www.ine.pt Accessed 20 May 2016

[7] http://repositorio.insa.pt/bitstream/10400.18/3205/3/Relat%C3%B3rio%20VIH_SIDA_2014.pdf Accessed 25 May 2016

[8] http://www.dgs.pt/?cr=29118 Accessed 25 May 2016

[9] http://www.who.int/tb/country/data/profiles Accessed 25 May 2016

[10] http://www.who.int/tb/publications/global_report/en Accessed 25 May 2016

[11] http://ipst.pt Accessed 3 June 2016

[12] http://www.acss.min-saude.pt Accessed 11 August 2016

[13] https://www.dgs.pt/em-destaque/portugal-doencas-respiratorias-em-numeros-20151.aspx Accessed 27 May 2016

[14] Sa-Sousa A, Morais-Almeida M,  Azevedo LF, Carvalho R, Jacinto T, Todo-Bom A, Loureiro C, Bugalho-Almeida A, Bousquet J,  Fonseca JA (2012) Prevalence of asthma in Portugal - The Portuguese National Asthma Survey. Clin Transl Allergy 2:15. doi:  10.1186/2045-7022-2-15

[15] http://dpoc.pt/dpoc-em-portugal Accessed 27 May 2016

[16] www.oecd.org/els/health-systems/49078977.xls Accessed 25 May 2016

[17] Bárbara C, Rodrigues F, Dias H, Cardoso J, Almeida J, Matos MJ, Simão P, Santos M, Ferreira JR, Gaspar M, Gnatiuc L, Burney P (2013) Chronic obstructive pulmonary disease prevalence in Lisbon, Portugal: the burden of obstructive lung disease study. Rev Port Pneumol. 19:96-105. doi: 10.1016/j.rppneu.2012.11.004. Epub 2013 May 8.

[18] Silva A, Amorim A, Azevedo P, Lopes C, Gamboa F (2016) Cystic fibrosis - characterization of the adult population in Portugal. Rev Port Pneumol. 22:141-5. doi: 10.1016/j.rppnen.2015.12.010. Epub 2016 Feb 15.

[19] Denning DW, Pleuvry A, Cole DC (2011) Global burden of chronic pulmonary aspergillosis as a sequel to pulmonary tuberculosis. Bull World Health Organ 89:864–872. doi:10.2471/BLT.11.089441

[20] Veríssimo C, Brandão J, Simões HL, Sabino R (2015) Dermatophyte infections in the Lisbon and Tagus valley. Abstract. Mycoses 58:220-1.

[21] Valdigem GL, Pereira T, Macedo C, Duarte ML, Oliveira P, Ludovico P, Sousa-Basto A, Leão C, Rodrigues F (2006) A twenty-year survey of dermatophytoses in Braga, Portugal. Int J Dermatol 45:822–827.

[22] http://www.who.int Accessed 25 May 2016

[23] OECD (2015), OECD Reviews of Health Care Quality: Portugal 2015: Raising Standards, OECD Publishing, Paris

[24] Lagrou K, Maertens J, Van Even E, Denning DW (2015) Burden of serious fungal infections in Belgium. Mycoses  58 Suppl 5:1-5. doi: 10.1111/myc.12389.

[25] Chrdle A, Mallátová N, Vašáková M, Haber J, Denning DW (2015) Burden of serious fungal infections in the Czech Republic. Mycoses 58:6-14. doi: 10.1111/myc.12384.

[26] Armstead J, Morris J, Denning DW (2014) Multi-country estimate of different manifestations of aspergillosis in cystic fibrosis. PLoS One 9:e98502. doi: 10.1371/journal.pone.0098502. eCollection 2014.

[27]https://www.dgs.pt/documentos-e-publicacoes/boas-praticas-e-orientacoes-para-o-controlo-da-asma-no-adulto-e-na-crianca-2-edicao.aspx Accessed 5 June 2016

[28] Denning DW, Pleuvry A, Cole DC (2013) Global burden of allergic bronchopulmonary aspergillosis with asthma and its complication chronic pulmonary aspergillosis in adults. Med Mycol 51:361–370.

[29] Denning DW, O’Driscoll BR, Hogaboam CM, Bowyer P, Niven RM (2006) The link between fungi and severe asthma: a summary of the evidence. Eur Respir J 27:615–626.

[30] Denning DW, Cadranel J, Beigelman-Aubry C, Ader F, Chakrabarti A, Blot S, Ullmann AJ, Dimopoulos G, Lange C; European Society for Clinical Microbiology and Infectious Diseases and European Respiratory Society (2016) Chronic pulmonary aspergillosis: rationale and clinical guidelines for diagnosis and management. Eur Respir J 47:45-68. doi: 10.1183/13993003.00583-2015.

[31] Yan X, Li M, Jiang M, Zou L-G; Luo F, Jiang Y (2009) Clinical characteristics of 45 patients with invasive pulmonary aspergillosis

retrospective analysis of 1711 lung cancer cases. Cancer 115:5018-5025. DOI: 10.1002/cncr.24559

[32] www.gecp.pt Accessed 10 August 2016

[33] Herbrecht R, Bories P, Moulin JC, Ledoux MP, Letscher-Bru V (2012). Risk stratification for invasive aspergillosis in immunocompromised patients. Ann N Y Acad Sci 1272:23–30

[34] Faria-Ramos I, Neves-Maia J, Ricardo E, Santos-Antunes J, Silva AT, Costa-de-Oliveira S, Cantón E, Rodrigues AG, Pina-Vaz C (2014) Species distribution and in vitro antifungal susceptibility profiles of yeast isolates from invasive infections during a Portuguese multicenter survey. Eur J Clin Microbiol Infect Dis 33:2241-7. doi: 10.1007/s10096-014-2194-8. Epub 2014 Jul 11.

[35] Nguyen MH, Wissel MC, Shields RK, Salomoni MA, Hao B, Press EG, Shields RM, Cheng S, Mitsani D, Vadnerkar A, Silveira FP, Kleiboeker SB, Clancy CJ (2012) Performance of Candida real-time polymerase chain reaction, β-D-glucan assay, and blood cultures in the diagnosis of invasive candidiasis. Clin Infect Dis  54:1240-8. doi: 10.1093/cid/cis200.

[36] Buchacz K, Baker RK, Palella FJ Jr, Chmiel JS, Lichtenstein KA, Novak RM, Wood KC, Brooks JT; HOPS Investigators (2010) AIDS-defining opportunistic illnesses in US patients, 1994-2007: a cohort study. AIDS 24:1549–59.

[37] Vos T, Flaxman AD, Naghavi M, Lozano R, Michaud C, Ezzati M, et al (2012) Years lived with disability (YLDs) for 1160 sequelae of 289 diseases and injuries 1990–2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet 380:2163–96

[38] Torres-Narbona M, Guinea J, Martinez-Alarcon J,   Muñoz P,  Gadea  I, Bouza E (2007) Impact of mucormycosis on microbiology overload: a survey study in Spain. J Clin Microbiol 45:2051-3.

[39] Bitar D, Van Cauteren D, Lanternier F, Dannaoui E, Che D, Dromer F, Desenclos J-C, Lortholary O (2009) Increasing incidence of zygomycosis (mucormycosis), France, 1997–2006. Emerg Infect Dis 15: 1395–1401.

[40] Diabetes: factos e números 2014. Relatório anual do observatório nacional da diabetes. Direção Geral de Saúde, 11/2014. Accessed 25 June 2016

[41] Gascón J, Torres JM, Jiménez M,   Mejias T, Triviño L, Gobbi F, Quintó L, Puig J, Corachan M (2005) Histoplasmosis infection in Spanish travellers to Latin America. Eur J Clin Microbiol Infect Dis 24:839–841. 

[42] Lopes MJ, Batista J, Trigo D, Cunha J, Patrícia Pacheco (2015). Histoplasmose africana: Apresentação atípica 40 anos após exposição. 14º Encontro Nacional de Atualização em infeciologia. 4-16 Outubro 2015,Porto, Portugal

Table 1. Portuguese population profile